NRAS Mutation Detection Kit
Available Products
Product Name/Description |
No. of Reactions*
|
Product Code |
---|---|---|
NRAS Mutation Analysis Kit |
50
|
NRAS-RT50 |
RAS c.59/117 Mutation Detection Kit † |
50
|
RASX-RT50 |
* Includes all controls. † For detection of KRAS c.59, NRAS c.59/117 somatic mutations. Available with purchase of NRAS-RT50, KRAS-RT50, or KRBR-RT50.
NRAS Mutations and Cancer
NRAS is a member of the RAS family of GTPases and plays a central role in the MAPK signaling pathway. Activating mutations in exon 2 (codon 12/13), exon 3 (codon 61), and exon 4 (codon 146) have been found in various cancers, including melanoma (13-25%), colorectal cancer (1-6%), lung cancer (1%), hepatocellular carcinoma (10%), myeloid leukemias (14%), and thyroid carcinoma (7%). The table below lists the mutations detected by the NRAS Mutation Detection kit.
Exon | Mutation Name | Nucleotide Change | Amino Acid Change |
---|---|---|---|
2 | G12C | c.34G>T | Glycine (G) to Cystein (C) |
G12D | c.35G>A | Glycine (G) to Aspartic acid (D) | |
G12S | c.34G>A | Glycine (G) to Serine (S) | |
G13V | c.38G>T | Glycine (G) to Valine (V) | |
G13R | c.37G>C | Glycine (G) to Arginine (R) | |
3 | Q61K | c.181C>A | Glutamine (Q) to Lysine (K) |
Q61R | c.182A>G | Glutamine (Q) to Arginine (R) | |
Q61L | c.182A>T | Glutamine (Q) to Leucine (L) | |
Q61H | c.183A>C & c.183A>T | Glutamine (Q) to Histidine (H) | |
4 | A146T | c.436G>A | Alanine (A) to Threonine (T) |
For expanded coverage, the RAS c.59/117 Mutation Detection Kit detects the following KRAS c.59, NRAS c.59/117 somatic mutations.
Exon | Mutation | Nucleotide Change | Amino Acid Change | COSMIC ID |
KRAS 3 | A59T | c.175G>A | Alanine (A) to Threonine (T) | 546 |
A59E | c.176C>A | Alanine (A) to Glutamic acid (E) | 547 | |
A59G | c.176C>G | Alanine (A) to Glycine (G) | 28518 | |
NRAS 3 | A59T | c.175G>A | Alanine (A) to Threonine (T) | 578 |
A59D | c.176C>A | Alanine (A) to Aspartic acid (D) | 253327 | |
NRAS 4 | K117R | c.350A>G | Lysine (K) to Arginine (R) | 4696722 |
EntroGen’s NRAS mutation detection kit is a polymerase chain reaction (PCR)-based assay that uses allele-specific primers to identify the presence of the mutations listed above. The testing procedure involves three (3) simple steps:
- Isolation of DNA from tumor biopsies, paraffin-embedded sections (FFPE), or fresh frozen tumors
- Amplification of regions of the NRAS gene using allele-specific primers.
- Detection of amplification product on a Real-Time PCR instrument.
This test can be completed in approximately 2 hours from isolation of DNA to test result.
Equipment and Materials
EntroGen’s NRAS mutation detection kit requires a real-time PCR instrument capable of detecting FAM and VIC fluorescent probes. This test includes reagents required for PCR amplification/detection, as well as validated reaction controls. Columns and reagents for DNA isolation are not included.
Intended Use
USA: EntroGen’s NRAS mutation analysis kit is provided for research use only (RUO). Not for use in diagnostic procedures. Europe: EntroGen’s NRAS mutation analysis kit is available for research (RUO) and diagnostic (CE-IVD) purposes.
Bibliography of studies using this product
Cetuximab in Treatment of Metastatic Colorectal Cancer: Final Survival Analyses and Extended RAS Data from the NORDIC-VII Study. Guren, Thomsen, Kure, Sorbye, Glimelius, Pfeiffer, Österlund, Sigurdsson, Lothe, Dalsgaard, Skovlund, Christoffersen, Tveit. Comparison of KRAS Mutation Tests in Colorectal Cancer Patients. Br J Cancer. 2017 May 9;116(10):1271-1278. Pubmed ID 28399112
Analysis of KRAS, NRAS, BRAF, and PIK3CA Mutations Could Predict Metastases in Colorectal Cancer: A Preliminary Study. Wojas-Krawczyk K, Kalinka-Warzocha E, Reszka K, Nicoś M, Szumiło J, Mańdziuk S, Szczepaniak K, Kupnicka D, Lewandowski R, Milanowski J, Krawczyk P. Adv Clin Exp Med. 2018 Aug 7. Pubmed ID 30085422